T cell-mediated cellular immune response is closely related to the occurrence,development,and therapeutic outcomes of solid tumors.Immune checkpoint inhibitor(ICI)immunotherapy has improved the survival prognosis of some solid tumor patients by correcting the host's cellular immune function.However,different patients have different responses to ICI treatment,effective and reliable biomarkers are urgently needed to monitor efficacy and adverse reactions.With the development of fundamental research in tumor immunology and the improvement of deep phenotyping of immune cells by flow cytometry,peripheral circulating cellular immune function assessment,as a new direction of precise diagnosis and treatment of tumors,has made significant progress in guiding clinical treatment selection,monitoring adverse reactions,evaluating treatment efficacy and prognosis,demonstrating good clinical application potential.
维普
万方数据